Multiple Sclerosis News and Research RSS Feed - Multiple Sclerosis News and Research

Multiple sclerosis (MS) is a severe autoimmune disease of the central nervous system that affects the brain and spinal cord, causing problems with muscle movement, balance and vision.

In MS, the protein coating called myelin, which protects nerves and helps electrical signals travel from the brain to the rest of the body, is damaged. The immune system, which usually fights infection, mistakes myelin for a foreign body and attacks it, stripping it from around the nerves. Exactly what causes this abnormal immune response is unclear, but research suggests a combination of both genetic and environmental factors.

The damaged myelin disrupts the transfer of nerve signals which may slow down, become distorted or stop altogether. This can cause severe symptoms ranging from vision loss through to muscle stiffness, loss of control over muscle movement, difficulties with balance and poor co-ordination.

Around 100,000 people in the UK have MS and it affects about three times as many women as men. The usual age at which diagnosis occurs is around 30, however, symptoms often first develop between the ages of 15 and 45.

Currently, there is no cure for MS but therapeutic approaches such as physiotherapy and steroid injections are used to manage the condition and ease symptoms.
Report: Global Multiple Sclerosis Drugs market to grow at 5.56% CAGR over 2013-2018

Report: Global Multiple Sclerosis Drugs market to grow at 5.56% CAGR over 2013-2018

Research and Markets has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. [More]
FDA accepts Mylan's ANDA filing for generic Copaxone 40 mg/mL

FDA accepts Mylan's ANDA filing for generic Copaxone 40 mg/mL

Mylan Inc. today announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration. [More]
New MS treatment found safe, tolerable in phase I clinical trials

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal. [More]
TxCell announces five new patents for core technology and ASTrIA platform

TxCell announces five new patents for core technology and ASTrIA platform

TxCell SA, a biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, today announces that five new patents for their technologies have been issued in the Unites States, Asia and Australia since the beginning of 2014. [More]
Balance board accessory can help people with MS reduce risk of accidental falls

Balance board accessory can help people with MS reduce risk of accidental falls

A balance board accessory for a popular video game console can help people with multiple sclerosis (MS) reduce their risk of accidental falls, according to new research published online in the journal Radiology. [More]
Research to understand how medical marijuana laws may influence overdose deaths

Research to understand how medical marijuana laws may influence overdose deaths

In states where it is legal to use medical marijuana to manage chronic pain and other conditions, the annual number of deaths from prescription drug overdose is 25 percent lower than in states where medical marijuana remains illegal, new research suggests. [More]
Study sheds new light on sleep drunkenness disorder

Study sheds new light on sleep drunkenness disorder

A study is shining new light on a sleep disorder called "sleep drunkenness". The disorder may be as prevalent as affecting one in every seven people. The research is published in the August 26, 2014, print issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Persons with MS may be able to improve self-awareness via task-oriented cognitive rehabilitation

Persons with MS may be able to improve self-awareness via task-oriented cognitive rehabilitation

A new study of self-awareness by Kessler Foundation researchers shows that persons with multiple sclerosis (MS) may be able to improve their self-awareness through task-oriented cognitive rehabilitation. [More]
Study finds a host of new clues on gene-environment interactions in Crohn's disease

Study finds a host of new clues on gene-environment interactions in Crohn's disease

A new study finds a wide range of epigenetic changes-alterations in DNA across the genome that may be related to key environmental exposures-in children with Crohn's disease (CD), reports Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America. [More]
New mouse model to open door to research on epilepsy, Alzheimer's

New mouse model to open door to research on epilepsy, Alzheimer's

University of Utah scientists have developed a genetically engineered line of mice that is expected to open the door to new research on epilepsy, Alzheimer's and other diseases. [More]
Study suggests that colds may temporarily increase stroke risk in kids

Study suggests that colds may temporarily increase stroke risk in kids

A new study suggests that colds and other minor infections may temporarily increase stroke risk in children. The study is published in the August 20, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. [More]
Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. [More]
Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS). [More]
Study identifies novel gene that controls nerve conduction velocity linked with MS

Study identifies novel gene that controls nerve conduction velocity linked with MS

A new study published in The American Journal of Pathology identifies a novel gene that controls nerve conduction velocity. [More]
Study examines the influence of unexpected task constraint on voluntary task switching

Study examines the influence of unexpected task constraint on voluntary task switching

Kessler Foundation scientists have published results of cognitive research that show the negative effects that unexpected task constraint, following self-generated task choice, has on task-switching performance. [More]
Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C. [More]
Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus. [More]
Global therapeutic market for BBB technologies expected to grow at 64.9% CAGR over 2014-2019

Global therapeutic market for BBB technologies expected to grow at 64.9% CAGR over 2014-2019

Reportlinker.com announces that a new market research report is available in its catalogue: Blood-Brain Barrier Technologies and Global Markets. [More]

Forward Pharma files Form F-1 registration statement for initial public offering of shares

Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]